Beta-Cyclodextrin As An Excipient In Drug Formulation
DOI:
https://doi.org/10.22270/ajprd.v9i4.1002Keywords:
Beta –Cyclodextrin, Cyclodextrin, Drug FormulationAbstract
After its discovery nearly 30 years ago, (2-Hydroxy –propyl) Beta –Cyclodextrin, a highly soluble derivative of Beta –Cyclodextrin, has been an authorized excipients of drug formulation in both the US and European pharmacopoeia. It is recommended for use in oral and parenteral formulations as a solubilizer and stabilizer. The majority of medications taken by mouth have low aqueous solubility and dissolution rates. Beta-Cyclodextrin that has been chemically modified Dynamic complex formation used to enchance the Low aqueous solubility, slow dissolution rate, and reduced drug stability. Cyclodextrin form inclusion complexes with appropriately sized guest molecules to improve aqueous solubility, physical chemical stability, and bioavailability of drugs. Cyclodextrin is a group of compounds made up of glucose monomers arranged in a donut form. They are non-reducing, crystalline cyclic oligosaccrides with a truncated core that produces a hydrophilic outer surface. Cyclodextrin and its derivatives have become common modalities for increasing oral bio availability and absorption rate as a result of these effects. Cyclodextrin has been positioned as an effective facilitating and usable excipients. This article discusses the widespread use of Cyclodextrin as excipients in drug formulations as well as recent Cyclodextrin developments.
Downloads
References
2. Uekama, K., and Otagiri, M., "Cyclodextrins in drug carrier systems," CRC Crit. Reu. Therap. Drug Carrier Systems, 3, I ( 1987).
3. Duchhene D, Ponchel G, Bochot A. New uses of cyclodextrins. Eur J Pharm Sci. 2005; 25(1): 51–62.
4. Hakkarainen B, Fujita K, Immel S, Kenne L, Sandstrom C. 1H NMR studies on the hydrogen-bonding network in mono-altro-β-cyclodextrin and its complex with adamantane-1-carboxylic acid. Carbohydr Res 2005; 340: 1539–1545.
5. Duan M, Zhao N, Ossurardottir IB, Thorsteinsson T, Loftsson T. Cyclodextrin solubilization of the antibacterial agents triclosan and triclocarban: formation of aggregates and higher-order complexes. Int J Pharm. 2005; 22 (9): 213–222.
6. D Duchene, G Ponchel, D Wouessidjewe. New developments in impro¬vement of drug solubility and availability by cyclodextrins. Proceedings of the ninth international symposium on cyclodextrins. 1999; 239–246.
7. Olesen NE, Westh P, Holm R. Displacement of Drugs from Cyclodextrin Complexes by Bile Salts: A Suggestion of an Intestinal Drug–Solubili¬zing Capacity from an In vitro Model. J Pharm Sci. 2016; 105(9):2640– 2647.
8. Huang Y, Zu Y, Zhao X, et al. Preparation of inclusion complex of api¬genin–hydroxypropyl–β–cyclodextrin by using supercritical antisolvent process for dissolution and bioavailability enhancement. Int J Pharm. 2016; 511(2):921–930.
9. Shimpi S, Chauhan B, Shimpi P. Cyclodextrins: Application in different routes of drug administration. Acta Pharm. 2005;55(2):139–156.
10. Biwer A, Antranikian G, Heinzle E. "Enzymatic production of cyclodextrins". ApplMicrobiolBiotechnol. 2002; 59 (6): 609–17.
11. CA Stanier, MJO Connell, HL Anderson and W Clegg. "Synthesis of fluorescent. 2001; 26(5): 222-235.
12. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: 1. Drug - solubilization and stabilization. J Pharm Sci 1996; 85 (10): 1017-25
13. Bergeron RJ. Cycloamylose-substrate binding. In: Attwood JL, Bavies JED, MacNicol DD, editors. Inclusion compounds. London: Academic Press, 1984: 391-443
14. Liu L, Guo Q-X. The driving forces in the inclusion complexation of cyclodextrins J Incl Phenom Macroc Chem 2002; 42: 1-14
15. Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formulation and delivery. Pharm Res 1997; 14 (5): 556-67
16. Connors KA. Population characteristics of cyclodextrin complex stabilities in aqueous solution. J Pharm Sci 1995; 84: 843-8
17. Rao VM, Stella VJ. When can cyclodextrins be considered for solubilizing pur- poses? J Pharm Sci 2003; 92: 927-32
18. Loftsson T, Magnusd ottir A, M asson M, et al. Self-association and cyclodextrin solubilization of drugs. J Pharm Sci 2002; 91: 2307-16
19. Loftsson T, Masson M, Brewster ME. Self-association of cyclodextrins and cyclodextrin complexes. J Pharm Sci 2004; 93: 1091-9
20. Loftsson T. Effects of cyclodextrins on chemical stability of drugs in aqueous Drug Stability 1995; 1: 22-33
21. Reddy MN, Rehana T, Ramakrishna S, Chowdary KPR, Diwan PV. ΒetaCyclodextrin Complexes of Celecoxib: Molecular-Modeling, Characterization, and Dissolution Studies. AAPS Pharm Sci Tech 2004; 6(1): 1-9.
22. Pravin A, Nagarsenker MS. Triamterene-β-CD system; preparation, characterization and in vivo evaluation. AAPS Pharm Sci Tec 2004; 5(1): 1- 8.
23. Sanjula B, Mona D, Kanchan K. Physicochemical characterization, invitro dissolution behavior, and pharmacodynamic studies of rofecoxibcyclodextrin inclusion compounds. AAPS Pharm Sci Tech 2005; 6(1): 14.
24. Moyano JR, Gines JM, Arias MJ, Rabasco AS. Study of dissolution characteristics of oxazepam via complexation with β-cyclodextrin. Int J Pharm 1995; 114: 95-102.
25. Xianu HW, Fei T, Zhijun J. Preparation and study of the 1:2 inclusion complex of carvedilol with β-cyclodextrin. J Pharm Biomed Anal 2004; 34: 517-523.
26. Marie W, Maggie A. Solid state studies of drug-cyclodextrin inclusion complexes in PEG-6000 prepared by new method. Eur J Pharm Sci 1999; 8: 269-281. .
27. Vamsi KM, Gowrisankar D. Role of Supercritical fluids in the Pharmaceutical Research-A Review. Indian J Pharm Edu Res 2007; 41(1): 10-17.
28. Liu HK, Lo YK, Tsai TR, Cham TM. Physicochemical characterizations of Osthole hydroxypropyl-β-cyclodextrin inclusion complexes with HighPressure Homogenization Method. Journal of Food and Drug Analysis 2010; 18(6): 391-397.
29. Gupta AK, Sehrawat S, Kumar A, Mishra DN. Solubility enhancement of cyproheptadine by formulating inclusion complexes. International Journal of Pharmaceutical Sciences Review and Research 2011; 9(1): 132-135.
30. 18. Fukaya H, Iimura A, Hoshiko K, Fuyumuro T, Noji S, Nabeshima T. A cyclosporin A/maltosyl‐α‐cyclodextrin complex for inhalation therapy of asthma. European Respiratory Journal 2003; 22(2): 213-219.
31. Nicolescu C, Arama C, Nedelcu A, Monciu CM. Phase solubility studies of the inclusion complexes of Repaglinide with β-Cyclodextrin and βCyclodextrin derivatives. Farmacia 2010; 58(5): 620-28.
32. Sevukarajan M, Thanuja B, Nair R. Novel Inclusion Complexes of Oseltamivir Phosphate-with ß Cyclodextrin: Physico-Chemical Characterization. J. Pharm. Sci. & Res 2010; 2(9): 583-589.
33. 21. Alsarra IA, Ahmed MO, Alanazi FK, Tahir KEH, Alsheikh AM, Neau SH. Influence of Cyclodextrin Complexation with NSAIDs on NSAID/Cold Stress-Induced Gastric Ulceration in Rats. Int J Med Sci 2010; 7: 232-239.
34. Bhosale AV, Hardikar SR, Jagtap RS, Patil NB, Dhawale SS, Shirsath SC. Formulation of beta cyclodextrin complexed controlled release matrix tablet of glipizide and its in-vitro evaluation. Int. J. PharmTech 2009; 1(3): 773-778.
35. Ribeiro et al. Cyclodextrin multicomponent complexation and controlled release delivery strategies to optimize the oral bioavailability of vinpocetine. J Pharm Sci 2007; 96(8): 2018-28.
36. Tirucherai GS, Mitra AK. Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of Ganciclovir. AAPS PharmSciTech 2003; 4(3): 1-12.
37. Wang S, Li D, Ito Y, Liu X, Zhang J, Wu C. An ocular drug delivery system containing zinc diethyldithiocarbamate and HPβCD inclusion complex--corneal permeability, anti-cataract effects and mechanism studies. J Pharm Pharmacol 2004; 56(10): 1251-7.
38. Mohamed MAH, Mahmoud AA. Formulation of Indomethacin eye drops via complexation with cyclodextrins. Current Eye Research 2011; 36(3): 208-216.
9. Tirucherai GS, Mitra AK. Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of Ganciclovir. AAPS PharmSciTech 2003; 4(3): 1-12.
39. Loftsson T, Brewter ME. Cyclodextrin as Pharmaceutical Excipients. Pharma Manager 1977; 5:22- 31.
40. Jug M, Becirevic-Lacan M, Kwokal A, Cetina-Cizmek B. Influence of cyclodextrin complexation on Piroxicam gel formulations. Acta Pharma 2005; 56: 223-236.
41. Ammar HO, Salama HA, Ghorab M, El-Nahhas SA, Elmotasem H. A Transdermal Delivery System for Glipizide. Current Drug Delivery 2006; 3(3): 333-341.
42. Roy SD, De GJ. Percutaneous absorption of nafarelin acetate, an LHRH analog, through human cadaver skin and monkey skin, Int. J. Pharm 1994; 110: 137–145.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.